CN117157280B - 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗慢性肾脏疾病的组合物 - Google Patents

包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗慢性肾脏疾病的组合物

Info

Publication number
CN117157280B
CN117157280B CN202280026646.XA CN202280026646A CN117157280B CN 117157280 B CN117157280 B CN 117157280B CN 202280026646 A CN202280026646 A CN 202280026646A CN 117157280 B CN117157280 B CN 117157280B
Authority
CN
China
Prior art keywords
compound
klotho
gene
oxazol
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202280026646.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN117157280A (zh
Inventor
郑东柱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kloso Science
Original Assignee
Kloso Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020220040453A external-priority patent/KR102463786B1/ko
Application filed by Kloso Science filed Critical Kloso Science
Publication of CN117157280A publication Critical patent/CN117157280A/zh
Application granted granted Critical
Publication of CN117157280B publication Critical patent/CN117157280B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280026646.XA 2021-04-01 2022-04-01 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗慢性肾脏疾病的组合物 Active CN117157280B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2021-0042955 2021-04-01
KR20210042955 2021-04-01
KR10-2022-0040453 2022-03-31
KR1020220040453A KR102463786B1 (ko) 2021-04-01 2022-03-31 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
PCT/KR2022/004706 WO2022211574A1 (ko) 2021-04-01 2022-04-01 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
CN117157280A CN117157280A (zh) 2023-12-01
CN117157280B true CN117157280B (zh) 2026-07-21

Family

ID=83456608

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280026646.XA Active CN117157280B (zh) 2021-04-01 2022-04-01 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗慢性肾脏疾病的组合物

Country Status (8)

Country Link
US (1) US12691102B2 (enExample)
EP (1) EP4317140A4 (enExample)
JP (1) JP7728030B2 (enExample)
CN (1) CN117157280B (enExample)
AU (2) AU2022248891A1 (enExample)
BR (1) BR112023020026A2 (enExample)
CA (1) CA3213910A1 (enExample)
WO (1) WO2022211574A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088770A (en) * 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
CN1440383A (zh) * 2000-04-28 2003-09-03 三共株式会社 PPARγ调制剂
KR20110137868A (ko) * 2010-06-18 2011-12-26 이화여자대학교 산학협력단 Ｉｎｔｅｒｌｅｕｋｉｎ―６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
WO2016176473A1 (en) * 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
KR20170024522A (ko) * 2015-08-24 2017-03-07 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
CN114502541A (zh) * 2019-10-02 2022-05-13 克洛索科学公司 诱导抗老化基因klotho的表达的化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318703B2 (en) * 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
CA2783555A1 (en) * 2009-12-16 2011-07-14 Eli Lilly And Company Therapeutic uses of soluble alpha-klotho
WO2018087132A1 (en) * 2016-11-10 2018-05-17 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3611521B1 (en) 2018-08-16 2026-05-27 GE Vernova Technology GmbH Apparatus for monitoring a condition of an electrical power transmission medium
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
KR20200145909A (ko) 2019-06-20 2020-12-31 주식회사 레이지소사이어티 면도날 자동주문 장치
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088770A (en) * 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
CN1440383A (zh) * 2000-04-28 2003-09-03 三共株式会社 PPARγ调制剂
KR20110137868A (ko) * 2010-06-18 2011-12-26 이화여자대학교 산학협력단 Ｉｎｔｅｒｌｅｕｋｉｎ―６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
WO2016176473A1 (en) * 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
KR20170024522A (ko) * 2015-08-24 2017-03-07 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
CN114502541A (zh) * 2019-10-02 2022-05-13 克洛索科学公司 诱导抗老化基因klotho的表达的化合物及其用途

Also Published As

Publication number Publication date
WO2022211574A1 (ko) 2022-10-06
AU2025202595A1 (en) 2025-05-01
AU2022248891A1 (en) 2023-10-26
CA3213910A1 (en) 2022-10-06
AU2022248891A9 (en) 2023-11-09
EP4317140A4 (en) 2025-04-09
JP2024512813A (ja) 2024-03-19
US12691102B2 (en) 2026-07-28
US20240216341A1 (en) 2024-07-04
JP7728030B2 (ja) 2025-08-22
CN117157280A (zh) 2023-12-01
BR112023020026A2 (pt) 2024-01-23
EP4317140A1 (en) 2024-02-07

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant